March 03, 2025 01:26 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Crucial to have Trump’s support, says Zelenskyy a day after fiery White House exchange | 'We're looking for peace, Zelenskyy wants Russia-Ukraine war to continue': Donald Trump after White House public spat | Volodymyr Zelenskyy refuses to apologise to Donald Trump after public spat over Russia-Ukraine war | 'Make a deal or we are out': Donald Trump tells Volodymyr Zelenskyy at White House | Himachal govt seeks fund from temple to support welfare schemes, BJP calls move 'shocking' | Injustice to opposition MLAs: Atishi writes to Delhi Assembly Speaker on suspension of 21 AAP lawmakers | We will leave for US tomorrow: Father of Indian student Neelam Shinde after urgent visa grant | 'Not joining BJP or floating any party': Abhishek Banerjee dismisses rumours of his split from TMC | Pune bus rape accused arrested after 75-hour manhunt | Finance Secretary Tuhin Kanta Pandey appointed as new SEBI chief
AstraZeneca
Image Credit: Wikimedia Commons

US phase 3 trial data shows 79% vaccine efficacy against symptomatic COVID-19: AstraZeneca

| @indiablooms | Mar 23, 2021, at 03:39 am

Ontario/IBNS: Advanced trial data from a US study on AstraZeneca coronavirus vaccine showed it is 79 per cent effective at preventing symptomatic COVID-19 and was 100 per cent effective in halting severe disease and hospitalization, said AstraZeneca in a statement on Monday.

It was reported by the investigators that the vaccine was effective across adults of all ages, including older people, which other countries with previous studies had failed to establish.

"These findings reconfirm previous results observed," said Ann Falsey of the University of Rochester School of Medicine, who helped lead the trial. "It's exciting to see similar efficacy results in people over 65 for the first time," CBC News reported. 

Also, no safety concerns related to the vaccine were identified by AstraZeneca's experts, including a rare blood clot that was identified in Europe.

It was found by the scientists that there was no increased risk of clots among the more than 20,000 people who got at least one dose of the shot, which was developed with Oxford University. 

"Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%. Amongst participants in the interim analysis, approximately 79% were white/Caucasian, 8% black/African American, 4% native American and 4% Asian, and 22% of participants were Hispanic," the pharmaceutical company said in a statement.

Although the vaccine has been approved for use in 50 countries, including Canada, it has not yet been approved in the US.

Canada is expected to receive 1.5 million doses of the AstraZeneca-Oxford product from the U.S. government this week.
 

(Reporting by Asha Bajaj)

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.